Friedrich-Alexander-Universitat Erlangen-Nürnberg

Sarah Wildenhain

Uwe Jacob

Karl-Peter Hopfner

Nadja Fenn

Ingo Schubert

Georg H Fey

Todd Braciak

Claudia C Roskopf

The present invention relates to a nucleic acid molecule encoding a chain myeloid capable of specifically binding to CD33, CD16 and CD123, wherein said nucleic molecule comprises: (a) a nucleic add molecule encoding a protein represented by SEQ ID NO:1; (b) a nucleic acid molecule represented by SEQ ID NO:2; (c) the nucleic add molecule of (b), wherein each thymine is replaced by urea; (d) a nucleic acid molecule encoding a protein having at least 98% sequence identity to the protein of (a); or (e) a nucleic add molecule that is degenerate with respect to the nucleic acid molecule of (b) or (c). The present invention further relates to a vector comprising the nucleic acid molecule of the invention, a host cell transformed or transfected with the nucleic acid molecule or the vector of the invention, as well as to a method for the production of a single chain myeloid capable of specifically binding to CD33, CD16 and CD123. Furthermore, the present invention also relates to a single chain myeloid capable of specifically binding to CD33, CD16 and CD123 encoded by the nucleic acid molecule of the invention, as well as to a composition comprising the nucleic acid molecule, the vector, the host cell and/or the single chain myeloid of the invention. Also, encompassed by the present invention are the nucleic acid molecule, the vector, the single chain myeloid and/or the composition of the invention for use in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome, as well as a method of treating acute myeloid leukaemia and/or myelodysplastic syndrome.

CD33-, CD16- and CD123-specific single chain triplebody

Growing community of inventors

Munich, Germany

Sarah Wildenhain